Use HOPE-3 To Justify Statin Use For Primary Prevention in Non-Whites

May 2016

You'll see more patients on statins for PRIMARY prevention.

We know statins improve outcomes for SECONDARY prevention. But evidence has been murkier in other patients...especially nonwhites.

Now the HOPE-3 study will provide more clarity for primary prevention patients with a 10-year CV risk of about 7.5% or higher.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote